Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema

78Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Treatment with 17 α-methyltestosterone and with some synthetic androgens prevents attacks of hereditary angioedema (HAE). However, the potential hepatotoxicity of 17 α-alkylated androgens raises the problem of long-term prophylactic use of these agents. Therefore we compared the efficacy in preventing HAE attacks of 17 α-alkylated steroids (danazol and stanozolol) with non-17 α-alkylated derivatives (quinbolone, nandrolone decanoate and mesterolone). As the latter group proved ineffective, it seems that a drug's efficacy in preventing HAE attacks is connected to its 17 α-alkylation. Moreover, our long-term observations with the minimum effective dose of danazol seem to indicate the absence of important collateral effects. © 1980.

Cite

CITATION STYLE

APA

Agostoni, A., Cicardi, M., Martignoni, G. C., Bergamaschini, L., & Marasini, B. (1980). Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. The Journal of Allergy and Clinical Immunology, 65(1), 75–79. https://doi.org/10.1016/0091-6749(80)90181-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free